{
    "clinical_study": {
        "@rank": "161301", 
        "acronym": "Revacom HD", 
        "arm_group": [
            {
                "arm_group_label": "Revaclear followed by FX", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "FX followed by Revaclear", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to show equivalent performance of the Revaclear dialyzer when\n      compared to a dialyzer with larger membrane surface area.\n\n      Study design: open, randomized, cross-over, multicentric, controlled prospective\n\n      Medical devices: Revaclear 200 versus FX 60 or Revaclear 400 versus FX 100, depending on\n      patient needs\n\n      Patients/sample size: 30 adult chronic hemodialysis patients\n\n      Treatment: Each patient will be treated by hemodialysis for one week (3 dialysis sessions)\n      with Revaclear dialyzers and one week (3 dialysis sessions) with FX dialyzers.\n\n      Objectives: intraindividual comparison of dialysis dose; reduction rates and total removal\n      of urea, phosphate, creatinine and \u00df2-microglobulin; albumin loss\n\n      Primary variable: dialysis dose Kt/V urea\n\n      Secondary variable: reduction rates and total removal of urea, phosphate, creatinine and\n      \u00df2-microglobulin\n\n      Safety variable: albumin loss, blood count"
        }, 
        "brief_title": "Performance Comparison of Revaclear With Larger Dialyzer", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Renal Failure Chronic Requiring Hemodialysis", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Failure, Chronic", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  chronic renal failure and stable treatment with hemodialysis or hemodiafiltration for\n             at least 3 months\n\n          -  patients aged 18 years or more\n\n          -  written consent to participate in the study (informed consent)\n\n          -  dialysis via native fistula or Gore-Tex graft capable of providing a blood flow rate\n             of at least 300 mL/min\n\n        Exclusion Criteria:\n\n          -  single-needle dialysis\n\n          -  pregnant and lactating women\n\n          -  participation in other interventional studies less than 3 months prior to study start\n\n          -  non-compliance with the dialysis prescription\n\n          -  hematocrit less than 28%\n\n          -  hospitalization\n\n          -  antibiotic therapy\n\n          -  active infection\n\n          -  active cancer\n\n          -  known positive serology for HIV, hepatitis B or C\n\n          -  serious hemostasis disorders\n\n          -  any comorbidity possibly conflicting with the study purpose or procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722695", 
            "org_study_id": "1499"
        }, 
        "intervention": {
            "arm_group_label": [
                "Revaclear followed by FX", 
                "FX followed by Revaclear"
            ], 
            "description": "Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).\nThe order of dialyzers used will be randomly assigned to the patient at randomization.", 
            "intervention_name": "Dialyzer comparison", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }, 
                    "name": "Medical University Graz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8010"
                    }, 
                    "name": "Dialyseinstitut Prim. Dr. W. Gie\u00dfauf GmbH"
                }
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "HD Performance Comparison of Revaclear 200 and Revaclear 400 With Larger-surface Competitor Dialyzers", 
        "other_outcome": {
            "description": "Parameters are hemoglobin concentration (g/dL), hematocrit (%), thrombocyte concentration (G/L), erythrocyte concentration (T/L), leukocyte concentration (G/L).", 
            "measure": "Blood count", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks (start and end of 6 consecutive dialysis sessions)"
        }, 
        "overall_official": {
            "affiliation": "Medical University Graz, Austria", 
            "last_name": "Alexander Rosenkranz, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Austria: Austrian Medicines and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Calculation from pre and post plasma urea concentration or urea nitrogen, session length, ultrafiltration volume and post dialysis weight. Dialysis dose does not have a unit of measure.", 
            "measure": "Dialysis dose Kt/V urea", 
            "safety_issue": "No", 
            "time_frame": "2 weeks (6 consecutive dialysis sessions)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722695"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Calculation from pre and post dialysis plasma concentrations. Unit of measure is percentage (%).", 
                "measure": "Reduction rate of urea, creatinine, phosphate and \u00df2-microglobulin", 
                "safety_issue": "No", 
                "time_frame": "2 weeks (6 consecutive dialysis sessions)"
            }, 
            {
                "description": "Calculation from measured concentration in integrated dialysate sample over entire treatment, dialysate flow rate, treatment duration and ultrafiltration volume. Unit of measure is g or mg per treatment.", 
                "measure": "Total removal of creatinine, phosphate and \u00df2-microglobulin", 
                "safety_issue": "No", 
                "time_frame": "2 weeks (6 consecutive dialysis sessions)"
            }, 
            {
                "description": "Calculation from measured concentration in integrated dialysate sample over entire treatment, dialysate flow rate, treatment duration and ultrafiltration volume. Unit of measure is g or mg per treatment.", 
                "measure": "Albumin loss", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks (6 consecutive dialysis sessions)"
            }
        ], 
        "source": "Gambro Dialysatoren GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gambro Dialysatoren GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}